Home
Kiromic

Kiromic Market Share Analysis for May 2026

Percent of Cancer deaths in the US potentially treatable by immunotherapy drugs

Industry: N/A

Domainkiromic.com

Year Founded2006

Employees51 - 200

Annual Revenue$5M - $10M

Kiromic

Kiromic (including company regionals)

kiromic.com

See more website traffic and engagement information

Kiromic Revenue up to May 2026 is 5M - 10M

revenue generated by Kiromic top domains

Kiromic top domains revenue over 3 years

Revenue for Kiromic top domains

kiromic.com5M - 10M

See more with Sales Intelligence

Total visits to Kiromic's top domains

Understand Kiromic market share and potential market reach.

Total visits last 3 months

No Data to Display

Avg. visit duration in Kiromic's top domains

Analyze Kiromic engagement metrics.

Average visit duration last 3 months

No Data to Display

Avg. pageviews on Kiromic's top domains

See how Kiromic keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

No Data to Display

Kiromic top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by Kiromic

These are the website technologies, by industry, used by Kiromic top domains

Widget (3)

Twemoji

Mobile (2)

Meta Viewport

Audio Video Media (1)

Vimeo

Content Management System (1)

WordPress

More Technologies

4

See all

News & Signals from Kiromic

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsKiromic Biopharma, Inc. is developing off-the-shelf gamma delta T-cell therapies.Texas-based Kiromic is developing off-the-shelf gamma delta T-cell therapies.

NewsKiromic Biopharma, Inc. has issues with failing to disclose material information.Kiromic BioPharma is charged for failing to disclose material information about Kiromic's two cancer fighting drug candidates.

NewsKiromic Biopharma, Inc. is developing two cancer fighting drugs.In this case, Kiromic was working on developing two cancer fighting drugs called "ALEXIS-PRO-1" and "ALEXIS-ISO-1," and filed two Investigational New Drug ("IND") applications with the FDA.